Background Skeletal bone accretion occurs throughout childhood. The integrity of this process can influence future adult bone health and the risk of osteoporosis. Although surveillance of children who are at risk of poor bone accretion is important, the most appropriate method to monitor childhood bone health has not been established. Previous investigators have proposed using bone age (BA) rather than chronological age (CA) when interpreting bone mineral density (BMD) values in children. Objective To investigate the value of BA assessment for BMD measurement in a cohort of children at risk of poor accretion.
Introduction
Bone fragility and its attendant risk of nontraumatic fracture-a condition commonly referred to as osteoporosis-is associated with significant morbidity and reduction in quality of life [1, 2] . Although several factors contribute to overall bone strength, the primary determinant is bone mass, or bone mineral density (BMD) [3, 4] . The process of bone accretion occurs throughout childhood, but maximum accrual occurs during the adolescent period [5] . Importantly, adult bone health can be negatively affected if accrual of peak bone mass in adolescence is compromised [6] . Conversely, interventions designed to optimize peak bone accrual during this critical period can reduce the risk of future bone fragility [1] . Therefore, it is important to monitor children who are at risk of developing low BMD so that ameliorative interventions can be appropriately instituted.
In adults, BMD is typically measured by either dualenergy X-ray absorptiometry (DXA) or quantitative computed tomography (QCT). Both methods generate a T-score (defined as the number of standard deviations above/below the average BMD value for young healthy women) that correlates well with bone fragility and risk of fracture [3] . This score represents the degree of bone loss since peak bone mass was achieved. Because children have yet to reach peak bone mass, Z-scores (defined as the number of standard deviations above/below the average BMD for ageand gender-matched controls) are utilized rather than Tscores. Thus, values in pediatric patients have been predominantly compared to normative populations that are age-and gender-matched [7] .
Unfortunately, because physiological maturation rates can be disparate among children of the same age, it is unclear whether chronological age (CA) used to generate Zscores is the best predictor of actual physiological bone status [8] . In children with abnormal physiological maturation, the applicability of CA is even more uncertain [9] . Pediatric endocrinologists commonly use estimations of bone age (BA) in the clinical evaluation and monitoring of aberrant growth patterns. Because BA is presumed to correlate better with physiological maturity, some investigators have proposed using this measurement rather than CA when interpreting BMD values in children [9, 10] .
In a cohort of pediatric patients with a brain tumor at risk of or with known endocrinological dysfunction, we investigated the value of BA assessment for BMD measurement in children. We hypothesized that CA and BA would differ to a significant degree in this cohort and that this difference would affect the interpretation of BMD.
Materials and methods
After our institutional review board had approved this study, an institutional database search annotated all patients who had undergone a QCT scan and BA analysis at St. Jude Children's Research Hospital for a variety of clinical indications between October 2000 and May 2006. Of these, 186 children were identified as having a primary brain tumor. Because inclusion for analysis required that both examinations be conducted within 6 months of each other, 23 children were excluded. The final cohort was thus composed of 163 children. For patients with multiple examinations, the most recent data were used for analysis. Cohort demographic and diagnostic information was abstracted from an electronic medical record that is updated with each patient visit.
Initial tumor diagnosis was based on results of clinical, radiographic, and (when available) histopathological analyses. The diagnosis was confirmed by review of the medical and pathology records, and coded as one of the following: embryonal tumor, ependymoma, glioma, germ cell tumor (GCT), craniopharyngioma (CP), or choroid plexus carcinoma. Primitive neuroectodermal tumors (including medulloblastoma), pineoblastoma, and atypical teratoid/rhabdoid tumor comprised the embryonal group. Gliomas included neuronal/mixed neural-glial, astrocytic, and oligodendroglial tumors. On the basis of MRI, we classified tumor location as optic nerve only, cerebrum (including hemispheres and basal ganglia), diencephalon (including optic chiasm/tract, hypothalamus, and thalamus), pineal, posterior fossa (including brainstem and cerebellum), and spinal cord. With the exception of optic nerve tumors, if the tumor overlapped more than one of the above regions, the site with predominant involvement was coded as the primary site.
The cohort's endocrine records were reviewed and conditions that might have contributed to aberrant patterns of growth or bone accretion were documented. Children who lacked salient clinical signs, symptoms, or laboratory values suggesting hormonal dysfunction were presumed to have a normal endocrine status. Otherwise, specific diagnoses were based upon an assessment of clinical signs and symptoms, results of random or dynamic testing including spontaneous overnight secretion of thyroidstimulating hormone (TSH) [11] , thyroid-releasing hormone (TRH) stimulation [12] , overnight metyrapone testing [12, 13] , insulin-induced hypoglycemia [14] , low-dose adrenocorticotropic hormone (ACTH) stimulation testing [12] , leuprolide stimulation testing [15] , stimulation of growth hormone secretion with arginine, L-dopa, clonidine or hypoglycemia, and also on the intended outcomes of specific pharmacologic interventions.
Precocious puberty was coded for girls who experienced onset of puberty either before reaching a CA and/or BA of 8 years or were ≥8 years at onset of puberty, but, because of concerns for undesired outcomes of final height and/or delayed cognitive-emotional capacity, their development was pharmacologically suppressed. In boys, precocious puberty was coded for those patients who experienced the onset of puberty before 9 years of age (CA and/or BA) or those who were ≥9 years at onset of puberty, but, because of concerns for undesired outcomes of final height and/or delayed cognitive emotional capacity, their development was pharmacologically suppressed. An advanced BA was not required to categorize patients with precocious puberty.
In children who had the onset of puberty at a CA or BA that was older than the precocious categories, if their predicted heights decreased with advancing features of puberty, and the rate of changes in BA maturation exceeded their change in CA, the relative pace of these children's puberty was frequently considered excessively rapid. These children with rapid-tempo puberty were often treated with luteinizing hormone-releasing hormone (LHRH) agonists to prolong their opportunity to grow. However, if children had relatively rapid changes in pubertal development and advancement in BA but lacked decreasing or abnormally short predicted final heights and were not treated with LHRH agonists, they were categorized as rapid tempo of puberty without intervention. Additionally, in order to maximize the benefit from GH therapy, some pubertal children with documented or suspected GH deficiency and poor predicted heights were treated with LHRH agonists and categorized as pubertal suppression to maximize height. For analysis, all children with evidence of precocious or rapid-tempo puberty were considered together as early-onset puberty.
In this heterogeneous cohort, no single arbitrary CA or BA was consistently referenced in the clinical notes as differentiating excessively delayed puberty compared to stalled puberty or incomplete sexual maturation. If the clinical notes indicated that the intention of sex hormone therapy was to imitate a graduated progression of pubertal changes, the category of delayed puberty was applied. If the intention of sex hormone therapy was to simulate late adolescent or adult physiology, then the category of hypogonadism was applied.
In children with a history of thyroid cancer or small thyroid nodules of indeterminate nature, administration of levothyroxine to produce some suppression of the TSH level was categorized as purposeful TSH suppression. For the purposes of categorizing the cohort, there was no differentiation of the relative magnitude of TSH insufficiency. Thus, children with evidence of partial or full TSH deficiency were labeled as central hypothyroidism. Children with elevated levels of TSH were categorized as primary hypothyroidism.
Unless the preponderance of laboratory and clinical features supported ACTH deficiency, children with a high index of suspicion for ACTH deficiency were not typically committed to maintenance therapy with glucocorticoids but were advised to make use of stress dosing of glucocorticoids for any acute illness. In the analysis of this cohort, children who only had recommendations for stress dosing of glucocorticoids were separated from children on daily maintenance glucocorticoid therapy.
Clinical record review did not disclose a single absolute definition of growth hormone deficiency (GHD). If children were treated with growth hormone for any length of time, they were categorized as GHD, on treatment. If growth hormone therapy was not utilized despite data to support GH deficiency, these children were categorized as GHD, off treatment. Children were categorized as having multifactorial short stature if they had past or present conditions associated with impaired growth but did not have laboratory values to support GHD.
Radiographic technique
QCT scan of the lumbar spine was performed with a Siemens Somatom-Plus spiral CT scanner (Siemens, Iselin, NY) and Mindways QCT Calibration Phantoms and software (Mindways Software, South San Francisco, CA). BMD was determined by obtaining direct axial images of the first and second lumbar vertebrae (trabecular bone) as localized from a sagittal scout image. BMD (in milligrams per cubic centimeter) was recorded for the individual bodies and the mean value was calculated. For BA measurement, a radiograph of the left hand and wrist was obtained and assessed using the method of Greulich and Pyle [16] . A total of four readers, all pediatric radiologists with a Certificate of Added Qualifications (CAQ), were identified.
Z-score calculation Z-scores based on CA (CA-QCT) were calculated by the manufacturer's software for each subject's BMD value (using the average values from L1-L2) as the number of standard deviations from the mean age-and gendermatched reference values provided by the manufacturers of the instruments. For comparative analysis of Z-score values based on BA analysis (BA-QCT), BA was substituted for CA using the same gender-matched reference values provided by the manufacturers of the instruments.
Statistical methods
Analysis was conducted using SAS version 9 and Stat Xact 5. All continuous variables were tested for normality using the Shapiro-Wilk test. We tested for a significant difference between CA-QCT and BA-QCT using the Wilcoxon signed ranks test. A robust linear regression model was constructed using BA-QCT as the response variable and CA-QCT as a covariate. Robust linear regression identifies outliers and/or leverage points in the data and provides stable results in their presence.
Clinical and demographic variables (all were categorical) were tested for association with outlier status. For those variables that had two categories (i.e. binary), the Fisher exact test was used. For variables with more than two unordered (i.e. nominal) levels, this test was generalized to the Fisher-Freeman-Halton test. To account for the number of statistical tests performed in this analysis, we controlled the experiment-wise type I error at the 0.05 level using the Bonferroni correction, which yielded a nominal level for significance of 0.003.
Results

Cohort characteristics
Cohort demographic, tumor, and radiation treatment information is presented in Table 1 . The median age at diagnosis for primary brain tumor in this cohort was 4.2 years (0.3 to 14.0 years). The median interval in years from diagnosis to first study (either BA or QCT, whichever came earliest) was 6.8 years (1.1 to 17.0 years). The median age at time of first study was 13.1 years (3.2 to 19.1 years) . Most children were referred for BA by the Division of Endocrinology in the course of evaluation and monitoring of growth and puberty trends. QCT was typically obtained as part of a research protocol or after assessment with endocrinology.
Comparison of CA-QCT and BA-QCT
The median CA at the time of the QCT scan was 13.1 years (3.3 to 19.1 years). The median BA was 13 years (3.0 to 17.0 years). The median CA-QCT Z-score was −1.21 (−4.57 to 2.12). The median BA-QCT Z-score was −1.20 (−4.62 to 2.00). Overall, no significant difference between CA-QCT and BA-QCT Z-scores was detected in this cohort (P=0.056). Furthermore, as expected based on robust regression analysis, we found that these two methods of determining QCT Z-scores were significantly associated with each other (P<0.0001, r 2 =0.74). The relationship between CA-QCT and BA-QCT Zscores is illustrated in Fig. 1 . Both graphs depict a significant degree of association between these tests. However, the first graph demonstrates several outliers (n=18) that were mathematically confirmed using robust regression analysis.
Analysis for outliers
To better account for the difference between the CA-QCT and BA-QCT Z-scores in 18 children, further analyses using multiple demographic and clinical covariates were completed (Table 2) . After applying the Bonferroni correction, only gender was found to be significantly associated with outlier status (P=<0.0001; 100% of the outliers were from boys compared with 52% of the non-outliers).
Change in QCT Z-score as a function of patient age and gender
Because BMD accrual is a maturational process that changes over time, we explored the potential influence of age and gender upon QCT measurement. Figure 2 shows the differences in Z-scores between boys and girls with respect to age at the time of study. A higher degree of variance between CA-QCT and BA-QCT Z-scores was noted in boys between the ages of 11 and 15 years. A sideby-side comparison of CA-QCT and BA-QCT Z-scores by age is shown in Fig. 3 . These box plots were constructed by standard methods, with the bottom and top of the box representing the first quartile (25th percentile) and third quartile (75th percentile), respectively. The line within the box represents the median, and the whiskers extend to the most extreme data points within 1.5 times the interquartile range (IQR). Data points outside the whiskers are suspected outliers and are individually represented with a circle. Differences between the CA-QCT and BA-QCT Z-scores were again observed in boys between the ages of 11 and 15 years. Of note, the BA-QCT median Z-score, −0.9 (−3 to 0.6), is considerably less than the CA-QCT median Zscore, −0.2 (−1 to 0.8), in the 12-to 13-year-old boys. The BA-QCT median Z-score, −1 (−3 to −0.4), is greater than the CA-QCT median Z-score, −2 (−3 to −0.6), in 14-to 15-year-old boys.
Discussion
Bone health in children with brain tumors is affected by multiple factors including endocrine dysfunction [17] [18] [19] , previous irradiation [20, 21] , exogenous steroid exposure [22, 23] , limited mobility [24] [25] [26] [27] , and chronic anticonvulsant use [28, 29] . Consequently, many pediatric patients are diagnosed with BMD deficits [30] [31] [32] [33] . Consistent with recommendations from the Children's Oncology Group [34] , BMD assessments are routinely obtained at our institution in at-risk children. These results help to guide clinical practice including dietary advice and/or pharmaceutical intervention. Of note, our patients' median CA-QCT Z-score was low (−1.21) but was within two standard deviations of normal. Because interpretation of BMD is based upon a comparison of the child's bone status with that of a reference population, the calculated Z-score reflects the degree of congruence or deviation from a mean value of BMD established in healthy children of the same CA. In this cohort of children with primary brain tumors, we did not detect an overall statistically significant difference in Zscore whether measured by CA-QCT or BA-QCT (P= 0.056). That is, in general, our findings do not support utilizing a BA for adjusting BMD Z-score. However, further inspection of our dataset revealed that the Z-scores from 18 children (11%) that were mathematically determined to be outliers from the scores of the rest of the cohort, that is CA-QCT and BA-QCT were not well correlated in these children. Interestingly, all of the outliers were from boys and primarily between the ages of 11 years and 15 years at the time of their evaluation. Other clinical and demographic covariates were not significantly associated ( Table 2 ). The variance detected in CA-QCT and BA-QCT Z-scores among peripubertal boys (Fig. 2 ) might reflect the increased physiological rate of change in bone accretion that occurs during this period. Increased bone mineralization closely follows the rapid expansion of bone volume during the normal growth spurt in boys. Because the expected age of this critical period of mineralization is similar to the age seen in the outliers of our cohort, our data suggest that the rate of bone accretion is changing such that a small difference in maturity (BA vs. CA) greatly affects the expected BMD. Thus, similar to a previous report, the accuracy of a CA-derived BMD in peripubertal boys (healthy or not) is of concern [9] and might warrant adding BA adjustment to BMD evaluations for children exhibiting extremes of growth velocities.
Many of our patients had overlapping endocrine conditions that could have cumulative influences on skeletal growth and maturation. We expected some endocrine categories to have linkage with BMD trends. However, no covariate specific to endocrine conditions was found to be significantly associated with outlier status. In this regard, it is pertinent to note that, because of the highly selected nature of our cohort, the majority of our patients with hormonal dysfunction were receiving endocrine interventions that were intended to normalize their growth and maturation. This could have been expected to decrease the difference between CA and BA. Moreover, with regard to abnormal pubertal status that can affect bone maturation, all children with known precocious puberty were under suppression and only a small percentage of our cohort (3%) had delayed-onset puberty. Therefore, we suspect that no association between outlier status and hormone status was detected because, in general, our patients with hypopituitarism were monitored and treated. Given this bias, our results might not be able to be well generalized to all children at risk of or diagnosed with hypopituitarism. Furthermore, our findings should not be considered representative of all pediatric patients with brain tumor.
Other limitations and bias within this study must be disclosed. First, our data were generated by QCT and might not be applicable to the more commonly utilized application of DXA. Measurements from QCT were chosen for analysis in this study because QCT provides direct volumetric assessment of BMD, which is believed to be important in BMD assessment in growing children [35] [36] [37] , and because there is a relative dearth of information regarding the use of QCT in chronically ill children. Nonetheless, the selective nature of this sample might have imparted bias. Second, as discussed by others, our method of recalculation of Z-scores by substituting BA for CA has Fig. 3 Side-by-side comparison of CA-QCT and BA-QCT Z-scores by age and gender for (a) boys and (b) girls. The bottom and top of the box represent the first quartile (25th percentile) and third quartile (75th percentile), respectively. The line within the box represents the median, and the whiskers extend to the most extreme data points within 1.5 times the IQR. Data points outside the whiskers are suspected outliers and are individually represented with a circle not been empirically validated because QCT reference data are based on CA, not BA [9] . In general, BA studies were requested for evaluation and monitoring of patients with obvious or potential aberrant growth patterns that might have led to selection bias. Although the interval between the QCT scan and BA evaluation was no greater than 6 months, the elapsed time might have been sufficiently long to alter our results. BA interpretation was not central to this study and, thus, subjective determination might have limited reliability. Finally, this study was retrospective in nature and, like all such studies, was subject to data collection limitations. In this regard, an inconsistent record prevented the analysis of other potentially important bonealtering factors such as body mass, concomitant nonreplacement glucocorticoid use, and dietary calcium or vitamin D intake.
Given that our population consisted of children treated for cancer, additional risk from exposure to radiation from QCT should be considered. At our institution, we estimate that the effective dose of radiation to a patient ranges from 0.63 mSv to 1.29 mSv per patient per study (depending on age 1-10 years and mA of 50-100). Although this likely exceeds the estimated exposure received during DXA, it is considerably lower than many assume and can be justified by its judicious use in high-risk patients. Furthermore, the radiation exposure using QCT is limited to the upper lumbar spine as opposed to that from DXA, which includes the whole lumbar spine and is often performed in concert with a whole-body exposure. QCT provides a direct volumetric measurement of BMD, which, using DXA, can be problematic in a growing child. An estimated volumetric measurement with DXA must be calculated, which introduces error. The judicious use of QCT provides important information with regard to bone health in these medically complex children. Anecdotally, we have also found that because QCT is a technically faster study than DXA, it might be better tolerated in children with altered or delayed cognitive development thereby obviating the need for sedation, which has its own risks.
In this study, by utilizing QCT we determined that BA might affect BMD measurement in peripubertal boys. Furthermore, boys aged 12-13 years had less bone accretion than suggested by CA-QCT and boys aged 14-15 years had more bone accretion than suggested by CA-QCT. These findings are interesting and could influence treatment decisions. Unfortunately, because no prospective longitudinal measurements were available, the exact implications of these findings are unknown. A prospective study is being developed that would address whether BMD (measured by BA-QCT and CA-QCT) would change over time with respect to pubertal status or treatment/intervention. In addition, the relevance of BMD to fracture rate will also be assessed.
